Figure 3 from Early ctDNA Dynamics Predict Response to Mosperafenib in BRAF V600-Mutant Metastatic Colorectal Cancer

Le résumé fourni par la source

On-treatment ctDNA dynamics and response prediction. A, Median on-treatment ctDNA levels by treatment history: Log-transformed MTM/mL and change in log-transformed CFB. B, Across cycles, comparing BRAFi-naive (N) vs. BRAFi-experienced (Y) patients. BRAFi-naive (N) patients exhibited significantly deeper and more sustained ctDNA reductions compared with BRAFi-experienced (Y) patients. C and D, ctDNA dynamics by radiographic response: Median absolute levels (C) and CFB (D) stratified by best overall response. The dashed line in D indicates the −75% reduction threshold for molecular response. E, Kaplan–Meier analysis of molecular response: Patients achieving a −75% reduction in ctDNA by C1D15 showed significantly longer mPFS (281 vs. 43 days, P < 0.0001). F, Predictive value stratified by treatment history: Analysis showing that the durability of clinical benefit is linked to both the depth of molecular response and prior treatment status. G and H, Detailed trajectories by history and response: Combined stratification of absolute levels (G) and CFB (H) illustrating the distinct molecular patterns of naive partial responders (N_PR) vs. experienced progressors (Y_PD). CFB is expressed as a log ratio of MTM/mL. P values were calculated via the log-rank test. Dashed lines in D and E indicate mPFS. CFB is expressed in log difference. [Created in BioRender. Godfried Sie, C. (2026) https://BioRender.com/fnqpbyh.]

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.